JP2017535285A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535285A5
JP2017535285A5 JP2017543332A JP2017543332A JP2017535285A5 JP 2017535285 A5 JP2017535285 A5 JP 2017535285A5 JP 2017543332 A JP2017543332 A JP 2017543332A JP 2017543332 A JP2017543332 A JP 2017543332A JP 2017535285 A5 JP2017535285 A5 JP 2017535285A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535285A (ja
JP6594438B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/059532 external-priority patent/WO2016073890A1/en
Publication of JP2017535285A publication Critical patent/JP2017535285A/ja
Publication of JP2017535285A5 publication Critical patent/JP2017535285A5/ja
Application granted granted Critical
Publication of JP6594438B2 publication Critical patent/JP6594438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543332A 2014-11-07 2015-11-06 改善されたil−6抗体 Active JP6594438B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US62/077,105 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US62/087,448 2014-12-04
US201562247705P 2015-10-28 2015-10-28
US62/247,705 2015-10-28
PCT/US2015/059532 WO2016073890A1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Publications (3)

Publication Number Publication Date
JP2017535285A JP2017535285A (ja) 2017-11-30
JP2017535285A5 true JP2017535285A5 (cg-RX-API-DMAC7.html) 2018-12-13
JP6594438B2 JP6594438B2 (ja) 2019-10-23

Family

ID=54602042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543332A Active JP6594438B2 (ja) 2014-11-07 2015-11-06 改善されたil−6抗体

Country Status (32)

Country Link
US (3) US11142571B2 (cg-RX-API-DMAC7.html)
EP (3) EP3632931A1 (cg-RX-API-DMAC7.html)
JP (1) JP6594438B2 (cg-RX-API-DMAC7.html)
KR (2) KR102636726B1 (cg-RX-API-DMAC7.html)
CN (1) CN107249631B (cg-RX-API-DMAC7.html)
AU (1) AU2015342882B2 (cg-RX-API-DMAC7.html)
CA (1) CA2965689C (cg-RX-API-DMAC7.html)
CL (1) CL2017001135A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017005404A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170231A (cg-RX-API-DMAC7.html)
DK (2) DK4268843T3 (cg-RX-API-DMAC7.html)
EA (1) EA035199B1 (cg-RX-API-DMAC7.html)
ES (1) ES2756275T3 (cg-RX-API-DMAC7.html)
FI (1) FI4268843T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20251312T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046181T2 (cg-RX-API-DMAC7.html)
IL (1) IL251858B (cg-RX-API-DMAC7.html)
LT (1) LT4268843T (cg-RX-API-DMAC7.html)
MA (1) MA51554A (cg-RX-API-DMAC7.html)
MX (2) MX385206B (cg-RX-API-DMAC7.html)
MY (1) MY185114A (cg-RX-API-DMAC7.html)
PE (1) PE20171107A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500809B1 (cg-RX-API-DMAC7.html)
PL (2) PL3215530T3 (cg-RX-API-DMAC7.html)
PT (2) PT4268843T (cg-RX-API-DMAC7.html)
RS (2) RS67353B1 (cg-RX-API-DMAC7.html)
SA (1) SA517381458B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201703574VA (cg-RX-API-DMAC7.html)
SI (1) SI3215530T1 (cg-RX-API-DMAC7.html)
UA (1) UA122673C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016073890A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201702985B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
JP2019510078A (ja) * 2016-02-23 2019-04-11 セセン バイオ, インコーポレイテッド Il−6アンタゴニスト製剤およびその使用
CN110291108A (zh) * 2016-12-19 2019-09-27 格兰马克药品股份有限公司 新型tnfr激动剂及其用途
AU2018237359B2 (en) 2017-03-22 2024-06-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
TW202144410A (zh) 2020-03-13 2021-12-01 美商建南德克公司 抗介白素-33抗體及其用途
EP4126949A1 (en) 2020-03-24 2023-02-08 Genentech, Inc. Tie2-binding agents and methods of use
EP4228706A1 (en) 2020-10-15 2023-08-23 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
CN116554298A (zh) * 2022-02-25 2023-08-08 南京工业大学 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
CA3264497A1 (en) * 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (cg-RX-API-DMAC7.html) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
CA2466034C (en) 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
CN1658836A (zh) 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
CA2506230A1 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009521909A (ja) * 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング IL−6とIL−6Rαの複合体のgp130への結合を阻害する抗IL−6抗体
EP2004690A2 (en) 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008045140A1 (en) 2006-05-19 2008-04-17 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
KR101829776B1 (ko) * 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Il-6에 대한 항체 및 이의 용도
KR20160005378A (ko) 2007-09-14 2016-01-14 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 a 및 b를 포함하는 약학적 조성물
EA201000844A1 (ru) 2007-11-21 2011-10-31 Амген Инк. Связывающие wise агенты и эпитопы
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
RU2537139C2 (ru) 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
HUE026179T2 (en) 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
EP2324930B1 (en) 2008-09-12 2012-11-14 KDF Co., Ltd. Water-spouting device
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
KR20110091777A (ko) 2008-11-26 2011-08-12 글락소 그룹 리미티드 폴리펩티드, 항체 가변 도메인 및 길항제
US20120034212A1 (en) 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CA2804185C (en) 2010-07-12 2017-03-21 Covx Technologies Ireland Limited Multifunctional antibody conjugates
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US20150239970A1 (en) 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
SG11201510315TA (en) 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Similar Documents

Publication Publication Date Title
JP2017535285A5 (cg-RX-API-DMAC7.html)
JP6480338B2 (ja) Il−6アンタゴニストおよびその使用
JP2016504416A5 (cg-RX-API-DMAC7.html)
JP7107914B2 (ja) VE-PTP(HPTP-β)を標的化するヒト化モノクローナル抗体
JP2010528047A5 (cg-RX-API-DMAC7.html)
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
EP2021026A1 (en) Use of il-i antibodies for treating ophthalmic disorders
JP2011504872A5 (cg-RX-API-DMAC7.html)
IL240898A (en) Antibodies against a5c for the preparation of drugs for the treatment of related diseases cause an increase
KR102770849B1 (ko) 향상된 il-6 항체
TWI612059B (zh) 泛-ELR<sup>+</sup>CXC趨化因子抗體
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2016503412A5 (ja) Il−6アンタゴニストおよびその使用
JP2019510078A5 (cg-RX-API-DMAC7.html)
JP6033459B2 (ja) Bmp−6抗体
JP2014532072A5 (cg-RX-API-DMAC7.html)
US9932397B2 (en) VEGFA/Ang2 Compounds
CN104507964A (zh) P2x7受体拮抗剂和激动剂
US20240052034A1 (en) Multi-paratopic anti-pd-1 antibodies and uses thereof
JP2020536495A (ja) 抗lag−3抗体及びその使用
CN103003302B (zh) 人源化和嵌合抗-备解素抗体
IL273538B2 (en) Anti-trkb monoclonal antibodies and methods of use
JP2021507677A5 (cg-RX-API-DMAC7.html)
JP2011503094A5 (cg-RX-API-DMAC7.html)
KR20230010239A (ko) 항-il-33 항체의 제형물